DR-377 Characterising the mutational landscape and recurrent somatic driver events to uncover therapeutic susceptibilities in pancreatic cancer

Pancreatic Adenocarcinoma (PAAD) has the highest rate of morbidly for all solid tumours, and with pancreatectomy possible in <20% patients, a much deeper understanding of the molecular aetiology of PAAD is needed to develop novel therapeutic strategies. In order to enable the next phase of genomic discovery and build a mutational atlas for future Precision Oncology purposes in pancreatic cancer, we wish to create a harmonised genomic dataset spanning all stages, from pre-cancerous lesions, primary resectable tumours to metastatic disease. This study will provide foundational data for a wealth of studies, including (i) Access to the full repertoire of druggable mutations, ii) An accurate map of cancer driving mutations and the relative timing of their accrual, (iii) Identification of core cancer-related processes, (iv) An accurate map of the molecular subtypes for designing targeted therapies, (iv) Defining mutational processes and defective cellular processes.

Sehrish Kanwal, University of Melbourne Centre for Cancer Research (UMCCR), Australia